Patients with KRAS-mutant colorectal cancers do not respond to cetuximab, a monoclonal antibody against EGFR. A new proof-of-concept study presents a bispecific antibody with the ability to trigger EGFR degradation in LGR5+ cancer stem cells, and robust anti-tumor activity in KRAS-mutant and wild-type colorectal cancers.
- Norihiro Goto
- Ömer H. Yilmaz
